Showing results (111-120 of 123) with videos related to
Sort By:
Pageof 13
Seminars in Oncology|December 1, 1992
Drug discovery and development in the pharmaceutical industryL P Schacter, C Anderson, R M Canetta, et al.Cancer Treatment Reports|September 1, 1979
Toxic effects of cis-dichlorodiammineplatinum(II) in manD D Von Hoff, R Schilsky, C M Reichert, et al.Cancer Treatment Reports|August 1, 1977
Whatever happened to NSC--? An analysis of clinical results of discontinued anticancer agentsD D Von Hoff, M Rozencweig, W T Soper, et al.Cancer|October 15, 1984
Combination chemotherapy with cisplatin, methotrexate, bleomycin, and vincristine (CABO) in advanced squamous cell carcinoma of the head and neckM Rozencweig, P Dodion, U Bruntsch, et al.Annals of Internal Medicine|November 1, 1979
Risk factors for doxorubicin-induced congestive heart failureD D Von Hoff, M W Layard, P Basa, et al.Cancer Research|June 1, 1979
Adequacies and inadequacies in assessing murine toxicity data with antineoplastic agentsA M Guarino, M Rozencweig, I Kline, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1984
Randomized phase II trial of carminomycin versus 4'-epidoxorubicin in advanced breast cancerM Rozencweig, W ten Bokkel Huinink, F Cavalli, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 1, 1993
Longitudinal analysis of responses to oral didanosine therapy following zidovudine therapy in advanced infection with human immunodeficiency virusC McLaren, M Rozencweig, M Beltangady, et al.Blood|December 15, 1992
Effects of therapy with didanosine on hematologic parameters in patients with advanced human immunodeficiency virus diseaseL P Schacter, M Rozencweig, M Beltangady, et al.European Journal of Cancer & Clinical Oncology|February 1, 1983
Phase II study of amsacrine in solid tumors: a report of the EORTC Early Clinical Trial-GroupR De Jager, P Siegenthaler, F Cavalli, et al.Pageof 13